Ilvigrip

Phenylephrine Hydrochloride, Guaifenesin and Paracetamol, the active ingredients in Ilvigrip, are a decongestant, expectorant and analgesic presented as an oral dosage form for oral use. They treat nasal congestion, cough, headache, fever and minor body aches associated with cold or flu in adults and children.

GNH USA supplies Ilvigrip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality, regulatory compliance and reliable logistics for global distribution.

Ilvigrip combines a decongestant, an expectorant and an analgesic to relieve common cold and flu symptoms.

- Nasal congestion: reduces swelling of nasal mucosa and improves airflow. - Cough: loosens mucus and facilitates expectoration. - Fever and headache: lowers elevated temperature and eases pain. - Minor body aches: provides analgesic relief of flu‑related muscle discomfort.

Ilvigrip may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Nausea: occasional stomach upset. - Dizziness: transient light‑headedness. - Headache: mild pressure sensation. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): difficulty breathing, swelling, rash. - High blood pressure: sudden increase in systolic/diastolic values. - Liver injury: abnormal liver function tests or jaundice.

Before using Ilvigrip, consider the following safety measures.

- Assess cardiovascular status: avoid in uncontrolled hypertension. - Avoid concurrent MAO inhibitors: risk of hypertensive crisis. - Use caution in liver disease: monitor paracetamol exposure. - Limit use in children: follow pediatric dosing guidelines. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Ilvigrip can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - MAO inhibitors: may cause severe hypertension when combined with phenylephrine. - Other sympathomimetics: additive vasoconstrictive effects. - Monoamine oxidase inhibitors: increased risk of cardiovascular events.

Moderate Interactions (Monitor Closely): - Warfarin: paracetamol may enhance anticoagulant effect; monitor INR. - Antacids: may alter phenylephrine absorption, reducing efficacy.